Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, 2x2 factorial, randomized-controlled trial in
critically-ill patients with novel coronavirus disease 2019 (COVID-19) evaluating the
efficacy and safety of full-dose vs. standard prophylactic dose anticoagulation and of
antiplatelet vs. no antiplatelet therapy for prevention of venous and arterial thrombotic
events.